SESSION TITLE: Lung Cancer Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM
PURPOSE: The aim of study was our three-year experience in connection with pulmonary cancer survival and determinant prognostic factors.
METHODS: 255 consecutive cases with pulmonary cancer were studied for a three-year period (2009-2011) at University Hospital of Lung Diseases "Sh. Ndroqi " Tirana. All cases were confirmed by histopathology. Survival was studied for a period of 24 months. We studied the correlation of survival related to factors such as: TNM classification, gender, histological type, age of groups, treatment modality, and lymphocytes in blood. Evaluation of relative survival was realized with Kaplan-Meyer method. Changes are called significant for p <0.05.
RESULTS: Of 255 cases in the study males was 226 (88.6%) and female 29 (11.4%) cases (p <0.001). Regarding the gender, survival was better in female than males (10.2% vs.4.7% respectively), [p = 0.756]. Survival for the age adjusted group <45vjec was 33.3%, versus 11% for age 45-70 years and 5.6% for the age group> 70vjec, [p = 0.001]. Survival in stage IAB was 18%, stage IIAB was 15.7% and IIIA 13.3%. In advanced stages IIIB-IV was 9.5% versus 16.5% for stages I-IIIA, [p = 0.0124].Squamous cell carcinoma and large cell carcinoma have better survival (16.6% and 17.6% respectively), while oat cell carcinoma has the lowest survival (5.5%) [p = 0.0045]. Cases with lymphopenia had lower survival (14.5%), against cases with normal blood lymphocytes (30.6%) and lymphocytosis (21%) [p = 0.014]. Cases treated with surgery had higher survival (20%), compared to those treated with chemioradiotherapi and palliative care (11% and 6% respectively).
CONCLUSIONS: The data of our study show that lung cancer survival for 24 month was 18% in stage IAB, 15.7% in IIAB, 13.3% in IIIA.and 9.5% in stage IIIB-IV.The stage, gender,hystologic type,age,lymphopenia and surgery were the most determinant prognostic factors.
CLINICAL IMPLICATIONS: To evaluate the survival of patients with lung cancer according to prognostic determinants.
DISCLOSURE: The following authors have nothing to disclose: Perlat Kapisyzi, Dhimitraq Argjiri, Eugerta Dilka, Armela Cuko, Roland Kore, Jeta Beli, Elenka Shehu, Ornela Nuredini, Enkelejda Safjani, Eritian Tashi, Edlira Ndreu, Arben Tanka, Esmeralda Nushi, Ilir Skenduli, Mirela Tabaku
No Product/Research Disclosure Information